Results 261 to 270 of about 67,365 (299)

Glucagon-like peptide-1 receptor agonists and the eye

Current Opinion in Ophthalmology
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire   +2 more sources

Glucagon-like peptide-1 receptor

Current Biology
Michael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

Trends in Endocrinology & Metabolism, 2016
Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on ...
van Raalte, Daniël H, Verchere, C Bruce
openaire   +4 more sources

Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1

Biochemical Pharmacology, 2018
The glucagon-like peptide 1 receptor (GLP-1R) can be activated by a number of endogenous peptide hormones, including extended, processed, glycine extended and carboxy-terminally amidated versions of glucagon-like peptide 1 (GLP-1). While the main focus of the literature has been on the processed, amidated form, GLP-1(7-36)NH2, the other forms of this ...
Furness, S. G. B., Christopoulos, A., Sexton, P. M., Wootten, D.   +3 more
openaire   +4 more sources

Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists

Kardiologiia, 2014
In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov, L L, Kamynina, Z G, Akhmedova   +2 more
openaire   +2 more sources

Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy

Biochemical and Biophysical Research Communications, 2019
Glucagon-like peptide-1 (GLP-1) and its receptor, GLP-1R, are valuable tools in the therapy of type 2 diabetes mellitus. Although GLP-1R stimulation is also potentially applicable to neurological disorders, few investigators have evaluated its beneficial effects in neurological disease models.
Yuetao Wen, Kunlun Wu, Yanfeng Xie, Wei Dan, Yan Zhan, Quanhong Shi   +5 more
openaire   +2 more sources

[Glucagon-like peptide-1 receptor agonists].

Nihon rinsho. Japanese journal of clinical medicine, 2015
Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire   +1 more source

The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists

Current Medicinal Chemistry
Abstract: Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short
Haowen, Fang, Bing, Niu, Qin, Chen
openaire   +2 more sources

Glucagon-like peptide 1 receptor

AfCS-Nature Molecule Pages, 2005
Dieter Hoersch, Joerg Schrader, Ruediger Goeke   +2 more
openaire   +1 more source

Glucagon-like peptide-1 receptor agonists

2016
Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
openaire   +1 more source